The study, published in PLOS Pathogens by Yu Zhang, Peng Wang and colleagues at the People’s Hospital of Xinjiang Uygur Autonomous Region, focused on the viral gene K15, which sits at the right end of the KSHV genome and encodes a multi-pass transmembrane signaling protein. K15 exists in two highly divergent alleles, known as the prototype (P) and minority (M) forms. In their cytoplasmic signaling domains, the two variants share less than 33 percent amino acid homology, a degree of divergence that suggests they may engage different molecular partners inside infected cells and, potentially, shape disease in different ways.

Xinjiang, a historical crossroads on the Silk Road, offered an unusually informative setting. The region has a high prevalence of Kaposi sarcoma and co-circulating viral genotypes rarely seen together in Western cohorts. Of the 147 patients who passed quality control and genotyping, 107, or 72.8 percent, carried the K15M variant, while 40 carried K15P. That distribution echoes patterns reported in classic Kaposi sarcoma cohorts from Japan and Taiwan and hints that host genetic and evolutionary pressures in Central Asian populations may have favored the M form.

The clinical picture that emerged was striking and, at first glance, paradoxical. Patients carrying the M genotype were significantly less likely to be coinfected with HIV, at 10.3 percent versus 27.5 percent among P carriers, yet they showed higher levels of systemic inflammation, measured by the Systemic Immune-Inflammation Index (SII), the neutrophil-to-lymphocyte ratio, and neutrophil counts. They also suffered lower limb edema far more often, at 37.4 percent versus 20.0 percent, and were less likely to have mucosal involvement. After adjusting for tumor stage, demographics and CD4 T-cell counts, K15M carriage remained an independent predictor of edema, with 2.6-fold increased odds, and of a high inflammatory burden, with an adjusted odds ratio of 5.43 for elevated SII.

To probe whether inflammation actually lies on the causal path between viral genotype and edema, the team used causal mediation analysis, a statistical framework that decomposes an association into direct and indirect components. The Systemic Immune-Inflammation Index significantly mediated 29.0 percent of the genotype-associated effect on edema, with a P value of 0.009. A reverse mediation model, testing whether edema led to inflammation rather than the other way around, failed to reach significance, supporting inflammation’s position upstream in the pathway. Dose-response analysis sharpened the picture further: among K15M carriers, edema risk rose linearly with increasing SII, with an odds ratio of 1.58 per 500-unit increase, whereas no such gradient existed in K15P carriers. The inflammation-edema link, in other words, appears intrinsically tied to the viral genotype.

The mechanistic plausibility rests on the structure of the K15 protein. Its signaling capacity resides in a C-terminal cytoplasmic tail containing SH2- and SH3-binding motifs that recruit Src-family kinases and TRAF adaptor proteins to activate the pro-inflammatory NF-kB and MAPK pathways. The P form has been well characterized as mobilizing these cascades through specific tyrosine-based motifs. The M form, by contrast, shows reduced dependence on the canonical YEEV motif for NFAT activation, and the authors hypothesize that its structurally distinct tail may confer enhanced affinity for inflammatory adaptors or lack the negative regulatory phosphorylation sites present in the P type. Such differences could produce constitutive, unchecked signaling that sustains high-grade systemic inflammation, which in turn promotes vascular permeability and the tissue swelling that clinicians observe as edema.

The genotype also carried prognostic weight. Kaplan-Meier analysis showed significantly inferior progression-free survival among K15M carriers, with a log-rank P value of 0.017, and multivariate Cox modeling yielded an adjusted hazard ratio of 1.87, a borderline but robust estimate confirmed across multiple censoring scenarios in sensitivity analyses. Notably, the deleterious effect was most pronounced in patients with localized disease, where the hazard ratio reached 4.32, suggesting that viral biology can flag danger even when the tumor appears anatomically confined. A dedicated sensitivity analysis restricted to classic Kaposi sarcoma patients preserved the inflammatory signature of K15M, arguing against clinical subtype as a confounder.

To convert these biological insights into a usable clinical instrument, the researchers built a six-factor prognostic nomogram using LASSO Cox regression with cross-validation, maintaining an events-per-variable ratio of 11.2. The model anchors on the K15 genotype and visceral involvement, supplemented by CD4 count, procalcitonin, the lymphocyte-to-monocyte ratio and the neutrophil-to-lymphocyte ratio, the latter two selected over SII to avoid collinearity. The tool achieved a concordance index of 0.761, corrected to 0.743 after bootstrapping with 5,000 resamples, and time-dependent ROC analysis showed areas under the curve above 0.80 at one, two and three years.

The head-to-head comparison with conventional staging was decisive. The nomogram achieved an area under the curve of 0.830, significantly outperforming anatomical stage alone at 0.563 and visceral involvement alone at 0.530, with P values of 0.003 and below 0.001 respectively. Reclassification metrics confirmed substantial gains in predictive accuracy, and decision curve analysis demonstrated net clinical benefit across a wide range of threshold probabilities. When patients were stratified by nomogram score, the high-risk group showed a median progression-free survival of 11.0 months versus 40.0 months in the low-risk group, a separation with a P value below 0.0001 that held regardless of HIV status or tumor burden.

The authors are careful to frame their conclusions within the limits of a single-center, retrospective design. Edema was assessed qualitatively rather than with quantitative metrics, a small fraction of viral genotypes remained unclassified, possibly reflecting recombination or untyped variants, and the mediation results are presented as biologically plausible associations rather than definitive causal proof, since no wet-lab cytokine assays were performed on the archival samples. Even so, the implications are considerable. If the K15M genotype sustains an NF-kB-driven inflammatory program independent of immunodeficiency, then carriers may represent a subgroup amenable to anti-inflammatory or immunomodulatory strategies layered onto conventional therapy, with genotyping serving as a companion diagnostic. More broadly, the study argues that Kaposi sarcoma risk assessment should move from anatomical observation toward biology-driven precision oncology, incorporating the genetics of the virus itself into the clinical calculus, particularly in regions where the M genotype predominates.

Subject of Research: Association of KSHV K15 genetic variants with Kaposi sarcoma aggressiveness and inflammation

Article Title: KSHV K15 genetic heterogeneity is associated with Kaposi sarcoma aggressiveness through modulation of the host inflammatory microenvironment

Article References: Zhang, Y., Wang, P., Zhang, J., Wang, Y., Li, T., Ding, Y., & Kang, X. (2026). KSHV K15 genetic heterogeneity is associated with Kaposi sarcoma aggressiveness through modulation of the host inflammatory microenvironment. PLOS Pathogens, 22(10), e1014615. https://doi.org/10.1371/journal.ppat.1014615

Image Credits: AI Generated

DOI: 10.1371/journal.ppat.1014615

Keywords: KSHV, Kaposi sarcoma, K15 genotype, inflammation, herpesvirus, edema, prognostic nomogram, precision oncology, mediation analysis, NF-kB, HIV, viral genotyping

Kaposi sarcoma develops when HHV-8-infected cells acquire tumour-like properties and stimulate the formation of abnormal vascular networks. The disease can occur in people living with HIV, where immune suppression and HIV-associated inflammation may accelerate tumour development, but it also appears in classic form, most often in older adults and in particular geographic regions. Although both forms are driven by the same virus, their clinical settings are different. Comparing them offers researchers a way to distinguish immune changes linked to HHV-8 from those caused primarily by HIV infection, ageing or systemic immune suppression.

The tumour microenvironment is central to that comparison. Cancer cells do not act in isolation; they exchange chemical signals with neighbouring cells through cytokines, chemokines, growth factors and cell-surface receptors. In Kaposi sarcoma, these interactions can support blood-vessel growth, recruit inflammatory cells and create conditions that allow infected tumour cells to persist. The new analysis indicates that HHV-8 is a major organiser of this local environment, influencing how immune cells are distributed and how they function within the tumour rather than merely serving as the initiating infection.

HHV-8 has a sophisticated biological programme that alternates between latent and lytic phases. During latency, the virus maintains its genome in infected cells while producing a restricted set of proteins that help the cell survive and evade immune attack. During lytic reactivation, a broader group of viral genes is expressed, generating new virus and altering the surrounding tissue through inflammatory and angiogenic signals. Viral proteins and non-coding RNAs can interfere with antigen presentation, antiviral signalling and programmed cell death. These mechanisms may create an immunologically abnormal niche in which tumour growth and viral persistence reinforce one another.

The study’s emphasis on both HIV-associated and classic disease is particularly significant because the two settings may contain overlapping, but not identical, immune landscapes. HIV infection can reduce the number and effectiveness of important T-cell populations, while antiretroviral therapy may partially restore systemic immune function without completely normalising tissues affected by cancer. Classic Kaposi sarcoma, by contrast, arises without HIV-driven immune depletion, yet it can still display local immune dysfunction. The comparison therefore suggests that HHV-8 itself has a distinct capacity to remodel immune activity inside the tumour.

A detailed view of this environment can reveal why immune cells that are capable of recognising infected or malignant cells fail to eliminate them. Tumours may contain cytotoxic lymphocytes, macrophages and other immune populations, but their presence does not necessarily mean they are active. Persistent exposure to viral and tumour-derived signals can produce functional exhaustion, alter cell differentiation or encourage regulatory pathways that suppress attack. At the same time, inflammatory cells may release factors that promote vascular remodelling and tumour survival. Kaposi sarcoma thus illustrates how inflammation can be both an attempted defence and a resource exploited by cancer.

These findings have implications for treatment strategy. Current management of Kaposi sarcoma may include antiretroviral therapy for people with HIV, chemotherapy, local treatment and, in selected cases, immune-based approaches. If HHV-8-dependent signals help establish an immunosuppressive microenvironment, therapies aimed only at rapidly dividing tumour cells may leave important drivers of disease untouched. Mapping the interaction between viral proteins, immune checkpoints, endothelial cells and inflammatory mediators could help identify combinations that block tumour support while restoring effective immune surveillance.

The research also underscores why tissue-level analysis matters. Blood tests can describe systemic immune status, but they cannot fully show which cells are physically adjacent within a lesion, what signals they are receiving or whether immune cells have entered a productive anti-tumour state. Modern tumour profiling can integrate cellular composition with gene-expression patterns and spatial organisation, allowing scientists to examine the microenvironment as a structured biological system. Such approaches are especially valuable for virus-associated cancers, where a small population of infected cells may influence many uninfected neighbouring cells.

For viral oncology, Kaposi sarcoma remains an important model of how chronic infection can transform tissue biology without relying on a single genetic alteration in the conventional sense. The new findings place HHV-8 at the centre of a regulatory network linking viral persistence, immune modulation, inflammation and abnormal vessel formation. They also reinforce the idea that the differences between HIV-associated and classic Kaposi sarcoma cannot be explained solely by the presence or absence of HIV. Understanding how the virus reshapes its surroundings may ultimately lead to more precise treatments that target both the tumour and the biological environment that allows it to endure.

Subject of Research: HHV-8-dependent immune regulation and the tumour microenvironment in HIV-associated and classic Kaposi sarcoma.

Article Title: In-depth characterisation of the tumour microenvironment reveals HHV-8-dependent immune regulation in HIV-associated and classic Kaposi sarcoma.

Article References: Fulgenzi, C.A.M., Dalla Pria, A., Zhao, Y. et al. “In-depth characterisation of the tumour microenvironment reveals HHV-8-dependent immune regulation in HIV-associated and classic Kaposi sarcoma.” British Journal of Cancer (2026). https://doi.org/10.1038/s41416-026-03536-5

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03536-5

Keywords: HHV-8, KSHV, Kaposi sarcoma, HIV-associated cancer, classic Kaposi sarcoma, tumour microenvironment, immune regulation, viral oncology, cancer immunology, tumour immunity